New subcutaneous formulation of Celltrion Healthcares CTP13 biosimilar infliximab shows positive results for the treatment of active Crohns disease in data presented at Digestive Disease Week 2018

Data showed that the subcutaneous SC administration of CTP13 was comparable in terms of efficacy and safety with intravenous IV administration of CTP13 RemsimaÂInflectra As a global leader in biosimilars Ce...